Skip to main content
FHTX
NASDAQ Life Sciences

Foghorn Therapeutics Raises $50M in Direct Offering Priced at Premium to Market

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$6.27
Mkt Cap
$360.797M
52W Low
$2.945
52W High
$6.79
52W Position info
113% above low
Off High info
7.7% below high
Rel. Volume info
1.8× avg
Market data snapshot near publication time

FHTX has more than doubled off its 52-week low of $2.945.

Summary

Foghorn Therapeutics Inc. announced a direct offering of common stock and warrants, raising approximately $50 million in gross proceeds at an offering price of $6.71 per share, which is a premium to the current market price.


Key Events · Financing and Capital Events · FHTX

  • Significant Capital Raise

    Foghorn Therapeutics is raising approximately $50.0 million in gross proceeds through a direct offering of common stock and warrants.

  • Premium Offering Price

    The common stock and pre-funded warrants are being sold at an offering price of $6.71 per share, which is a premium to the current market price of $6.27.

  • Substantial Dilution

    The offering includes 2,030,314 shares of common stock and warrants to purchase an additional 12,872,814 shares, leading to significant potential dilution for existing shareholders.

  • Funding for Programs

    Net proceeds of approximately $49.6 million will be used to advance the company's preclinical and clinical programs and for general corporate purposes.


Analysis · FHTX · Life Sciences

This significant capital raise provides Foghorn Therapeutics with approximately $49.6 million in net proceeds to fund its preclinical and clinical programs and for general corporate purposes. The offering price of $6.71 per share, which is above the current trading price of $6.27, indicates strong investor confidence in the company's valuation and future prospects. While the offering is highly dilutive, the successful securing of substantial capital at a premium is a positive development for a clinical-stage biotechnology company, extending its operational runway and supporting its pipeline development without incurring underwriting fees.

At the time of this filing, FHTX was trading at $6.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $360.8M. The 52-week trading range was $2.94 to $6.79. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

FHTX - Latest Insights

FHTX
May 07, 2026, 7:11 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $4.68
Real-time Price: $4.85 info
Change: +$0.170 (+4%) info
Market Cap: $284.763M info
FHTX
May 07, 2026, 7:02 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.68
Real-time Price: $4.85 info
Change: +$0.170 (+4%) info
Market Cap: $284.763M info
FHTX
May 07, 2026, 7:01 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.68
Real-time Price: $4.85 info
Change: +$0.170 (+4%) info
Market Cap: $284.763M info
FHTX
Apr 30, 2026, 7:00 AM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $4.61
Real-time Price: $4.85 info
Change: +$0.2387 (+5%) info
Market Cap: $284.763M info
FHTX
Apr 21, 2026, 4:03 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $5.27
Real-time Price: $4.85 info
Change: -$0.420 (-8%) info
Market Cap: $284.763M info